The lawsuit, filed in 2001, claimed drugmaker Schering-Plough, which Merck acquired in 2009, agreed to pay Upsher-Smith at least $60 million to refrain from marketing its generic version of K-Dur, according to court documents.
The settlement is still subject to court approval, and both drugmakers deny any wrongdoing, according to the report. Merck and Upsher-Smith did not respond to Reuter’s request for comment.
More articles on supply chain:
Viewpoint: Why healthcare needs more ‘me too’ drugs
FDA safety warning: Diabetes drug causes higher risk of foot, leg amputations
Senate health commitee OKs FDA user fee reauthorization bill
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
